Is PJP a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

384 people get PJP articles and Market Currents by email alert.

Get email alerts on PJP »

HEADLINES:

Why 'Dr. Doom' Is Buying Stocks (Why I Will Wait On Stock ETFs)
Gary Gordon • Tue, Apr 30 • 15 Comments
Best And Worst ETFs And Mutual Funds: Health Care Sector
David Trainer • Thu, Apr 25 • 5 Comments
An ETF Portfolio For Lowering U.S. Stock Risk In The Months Ahead
Gary Gordon • Thu, Apr 11
Selecting Safer Growth And Income ETFs For The 2nd Quarter Pullback
Gary Gordon • Mon, Apr 1
The Best Pharmaceutical Investments
Catalyst Investments • Wed, Mar 20
Diminishing 'Wealth Effect' Requires ETF Portfolio Changes
Gary Gordon • Wed, Mar 13 • 1 Comment
PowerShares Dynamic Pharmaceuticals ETF: Big Pharma Looks Abroad to Continue Its Run
Morningstar • Mon, Mar 11 • 1 Comment
ETF Investors Need To Keep An Eye On These 3 Longer-Term Trends
Gary Gordon • Mon, Feb 25 • 1 Comment
Healthcare Check-Up: An Easy Portfolio For The New Paradigm
The Amalgamator • Mon, Jan 28 • 10 Comments
Merck Earnings Preview: Pharma Mega Cap Begins To Enhance Shareholder Value
Brian Gilmartin • Wed, Oct 24, 2012
Is Big Pharma The Real Tech Story?
Dana Blankenhorn • Tue, Oct 16, 2012 • 1 Comment
Upside / Downside Capture Ratio Can Help Identify Strong Investment Funds
Richard Shaw • Mon, Oct 1, 2012 • 10 Comments
Election Could Make Or Break Health Care ETFs
Tom Lydon • Tue, Sep 18, 2012
Healthcare ETFs React Differently To Supreme Court's Ruling
Gary Gordon • Thu, Jun 28, 2012 • 4 Comments
Top 10 Healthcare ETFs
David Fry • Tue, Jun 19, 2012 • 3 Comments
Not All Biotechnology ETFs Created Equal
Steven Breazzano • Fri, Jun 8, 2012 • 6 Comments
Playing Defense With Sector ETFs
Doug Wright • Thu, Jun 7, 2012 • 5 Comments
Moderate Risk Investors May Prefer A Conservative ETF Portfolio [Podcast]
Gary Gordon • Sun, May 27, 2012 • 5 Comments
3 Dynamic ETFs For A Risk-Off World
Gary Gordon • Wed, May 23, 2012
Biotech ETFs For An M&A Boom
Tom Lydon • Wed, May 16, 2012

To learn more about Seeking Alpha Pro, click here.

PowerShares Dynamic Pharmaceuticals ETF: Big Pharma Looks Abroad to Continue Its Run
Morningstar • Mon, Mar 11 • 1 Comment
Re-Evaluating Your Healthcare Exposure: A Sector ETF Overview
Morningstar • Thu, Mar 4, 2010

Why 'Dr. Doom' Is Buying Stocks (Why I Will Wait On Stock ETFs)
Gary Gordon • Tue, Apr 30 • 15 Comments
Best And Worst ETFs And Mutual Funds: Health Care Sector
David Trainer • Thu, Apr 25 • 5 Comments
An ETF Portfolio For Lowering U.S. Stock Risk In The Months Ahead
Gary Gordon • Thu, Apr 11
Selecting Safer Growth And Income ETFs For The 2nd Quarter Pullback
Gary Gordon • Mon, Apr 1
The Best Pharmaceutical Investments
Catalyst Investments • Wed, Mar 20
Diminishing 'Wealth Effect' Requires ETF Portfolio Changes
Gary Gordon • Wed, Mar 13 • 1 Comment
ETF Investors Need To Keep An Eye On These 3 Longer-Term Trends
Gary Gordon • Mon, Feb 25 • 1 Comment
Healthcare Check-Up: An Easy Portfolio For The New Paradigm
The Amalgamator • Mon, Jan 28 • 10 Comments
Merck Earnings Preview: Pharma Mega Cap Begins To Enhance Shareholder Value
Brian Gilmartin • Wed, Oct 24, 2012
Is Big Pharma The Real Tech Story?
Dana Blankenhorn • Tue, Oct 16, 2012 • 1 Comment
Upside / Downside Capture Ratio Can Help Identify Strong Investment Funds
Richard Shaw • Mon, Oct 1, 2012 • 10 Comments
Election Could Make Or Break Health Care ETFs
Tom Lydon • Tue, Sep 18, 2012
Healthcare ETFs React Differently To Supreme Court's Ruling
Gary Gordon • Thu, Jun 28, 2012 • 4 Comments
Top 10 Healthcare ETFs
David Fry • Tue, Jun 19, 2012 • 3 Comments
Not All Biotechnology ETFs Created Equal
Steven Breazzano • Fri, Jun 8, 2012 • 6 Comments
Playing Defense With Sector ETFs
Doug Wright • Thu, Jun 7, 2012 • 5 Comments
Moderate Risk Investors May Prefer A Conservative ETF Portfolio [Podcast]
Gary Gordon • Sun, May 27, 2012 • 5 Comments
3 Dynamic ETFs For A Risk-Off World
Gary Gordon • Wed, May 23, 2012
Biotech ETFs For An M&A Boom
Tom Lydon • Wed, May 16, 2012
What Should Investors Make Of Relative Weakness In The Transportation ETF?
Gary Gordon • Thu, Apr 26, 2012 • 5 Comments

There are no Transcripts on PJP.

Jim Lowell: Balancing your portfolio for spring

at MarketWatch.com (Apr 2, 2012)
Jim Lowell: Battening down the hatches for market storms

at MarketWatch.com (Sep 6, 2011)

PJP vs. ETF Alternatives

PJP Description

The PowerShares Dynamic Pharmaceuticals Portfolio (Fund) is based on the Dynamic Pharmaceuticals Intellidex Index (Index). The Fund will normally invest at least 90% of its total assets in common stocks that comprise the Index. The Index is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.
See more details on sponsor's website

Sector: Healthcare

Country: United States

Key Info

In Your Portfolio: A Guide to Sector ETFs, A Guide to Healthcare, Pharma and Biotech ETFs
Asset Class Performance: Themes & Subsectors, Sectors

All
| Earnings
| Dividends
| M&A
| On the move

Monday, May 6, 1:36 PM Merck (MRK -1.3%) gets no love today from the FDA's approval of Liptruxet late Friday, as the stock is likely dragged down with the rest of the big pharma names on the back of a CNBC report that criticizes their earnings so far. The article points to the fact that pharmaceutical companies have seen a 4.7% contraction in earnings, and a 3.2% drop in revenue this quarter. Why? Morningstar's Damien Cover says there are two primary reasons: FX impact, especially from the yen, and intensified generic competition from patent losses. Comment! [Healthcare, On the Move]
Monday, April 30, 2012, 5:20 AM Pure pharmaceuticals players, like AstraZeneca (AZN), Bristol-Myers (BMY) and Eli Lilly (LLY), are likely to face higher earnings pressure over the next three years than more-diversified firms like J&J (JNJ) or Bayer (BAYRY.PK), says Fitch. Cash-rich pure-players with a relatively weak R&D pipeline, like AZN, may be tempted to go on buying sprees. Comment! [Healthcare, Quick Ideas]
Tuesday, April 17, 2012, 1:29 PM Express Scripts (ESRX +2.5%) says prescription drug spending fell to 2.7% growth in 2011 - the slowest pace in 18 years - due to the introduction of generic medicines that tempered price increases. The company notes that the average co-payment for consumers fell to $12.02 a prescription from $12.10 a year before. Comment! [Healthcare]
Tuesday, April 3, 2012, 10:04 AM Push comes to shove as pricey life-saving cancer drugs run up against government austerity programs and private payers unwilling to share costs for drugs that run as high as $100K a year. While Big Pharma argues that advanced technology will save money on the development side, companies such as PFE, BMY, RHHBY, and BAYRY.PK run the risk of seeing reduced profits with government-mandated price cuts for their most expensive drugs. 4 Comments [Healthcare, Quick Ideas]
Wednesday, March 14, 2012, 2:33 PM Downsizing: Only two of the top ten drugmakers increased their promotional spending last year, according to analysis from Cegedim Strategic Data. Overall, global investment on sales and marketing declined 3.4% to $92B. Comment! [Healthcare]
Wednesday, January 18, 2012, 12:01 PM Research from Frost & Sullivan breathes some life into the potential for generic drug makers with its new projections that the global market for generics could tip the scales at $231B in 2017 - repping an annual growth rate of close to 10%. The biggest drivers for the stellar growth should be blockbuster drugs that fall off their patents and the "huge potential" for copycat drug sales in emerging markets such as China, India, and Brazil. Comment! [Healthcare, Quick Ideas]
Friday, January 13, 2012, 1:35 PM Affymax (AFFY -0.3%) CEO John Orwin says the days of biotech companies seeing their share price bid up on potential is over, as investors wait it out to see if firms hash out issues with reimbursements, regulatory hurdles, and safety concerns. "There was a time when products got full value prior to launch. I think we have now swung back in the other direction." Comment! [Healthcare]
Tuesday, December 27, 2011, 2:54 PM Reuters' John Wasik identifies health care as a sector that will grow in 2012 on the strength of a long-term demographic trend that is pushing up demand for medical services, devices, and pharmaceuticals. He argues that while big pharma ETFs could see a gain, a focus on generic pharmaceutical names looks to be an even better bet as governments and companies look to cut costs. Big pharma ETFs: XPH, IHE, PJP, PPH, DRGS. Generic pharma firms: IPXL, MYL, PRX, TEVA, WPI, PRGO. Comment! [Healthcare, Quick Ideas]
Tuesday, December 27, 2011, 5:25 AM It could be a very tough year for pharmaceutical firms, which face a slew of patent expiries and new costs from healthcare reforms. Market research firm CreditSights pegs Bristol-Myers (BMY) and Eli Lilly (LLY) as likely to be next year's hardest-hit pharmas, while Abbott (ABT) and J&J (JNJ) will remain relatively sheltered. Comment! [Healthcare]
Wednesday, December 14, 2011, 7:50 AM Fitch is establishing a negative 2012 outlook for pharmaceutical companies, arguing soft demand, patent expirations, and government spending cuts will take a toll on the industry; the patent expirations (I, II, III) are seen affecting LLY, BMY, and PFE the most. Fitch also sees pharmas responding to these challenges by stepping up their M&A activity. Comment! [Healthcare, Quick Ideas, M&A]
Tuesday, December 6, 2011, 12:48 PM Sanford Bernstein analyst Tim Anderson's take on Eli Lilly (LLY +3.3%) offers a surprisingly candid view on the roulette-like risks involved in betting on drug company stocks with his estimate that LLY could clear $9B in sales of solanezumab by 2020 or misfire completely with its investment. Anderson on the sector: "Eli Lilly and several of its competitors are willing to spend hundreds of millions of dollars on what is essentially a massive lottery ticket." Comment! [Healthcare, Quick Ideas]
Friday, September 23, 2011, 1:53 PM Shares of MannKind (MNKD +11%) go on a tear after the firm announces a plan to offer $370M in senior secured discount notes to be used in part to develop Phase 3 clinical trials of its AFREZZA product. The move follows up last month's FDA clearance on late-stage trials for the inhaled insulin therapy. 1 Comment [On the Move, Healthcare]
Wednesday, August 10, 2011, 12:08 PM Analysts continue to beat the drum for Pfizer PFE witnessed by JPMorgan reiterating an Overweight rating on shares with a $25 price target, following Goldman Sachs adding the firm to its Conviction Buy List yesterday. Shares are down 1.4%, standing as the leader for Dow components on the day. 5 Comments [Consumer, Healthcare]
Monday, August 1, 2011, 3:56 PM Citi lowers its price target on Auxilium Pharmaceuticals (AUXL -6.6%) to $22 from $27 saying expectations on revenue from the firm's Xiaflex are too high. Earlier the firm issued its own downward guidance on FY11 revenue derived from the drug to a range of $45M-$50M from $50M-$60M. Comment! [Healthcare, On the Move]
Monday, August 1, 2011, 8:37 AM Elan (ELN) shares jump +4.6% premarket after Acorda Therapeutics (ACOR) announces positive prescriber response for its AMPYRA treatment for MS patients. The drug is manufactured by Elan in a supply agreement with Acorda. Comment! [Healthcare, On the Move]
Thursday, July 21, 2011, 12:25 PM Shares of Alexion (ALXN +8.7%) pop after issuing upward guidance, and announcing it plans to launch its Soliris treatment for patients with aHUS in Q4. (PR) Comment! [On the Move, Healthcare]

Dr. Kris
Bear alert! Several industry group etfs showing signs of overextension: Timber $CUT, Biotech ($FBT, $BBH, $IBB), Pharma ($PJP)...
Mar 5, 1:55 PM
Reply (2)

• !Report Abuse
View all 2 replies
Dr. Kris: If you're in any of these, you might want to start putting in a trailing (mental) stop/loss; lighten up; or protect position.
Mar 5, 1:56 PM
• !Report Abuse
Hillbilly Stock Star: They look like Panda Bears! LoL!
Mar 5, 1:58 PM
• !Report Abuse
Add a reply...

140 characters

Dr. Kris
Darling of the Day: $BMY breaking out to a 10 year high. 3.9% yield. Pharma sector strong as ETF $PJP also at new high.
12/20/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Dr. Kris
Bear alert! Several industry group etfs showing signs of overextension: Timber $CUT, Biotech ($FBT, $BBH, $IBB), Pharma ($PJP)...
Mar 5, 1:55 PM
Reply (2)

• !Report Abuse
View all 2 replies
Dr. Kris: If you're in any of these, you might want to start putting in a trailing (mental) stop/loss; lighten up; or protect position.
Mar 5, 1:56 PM
• !Report Abuse
Hillbilly Stock Star: They look like Panda Bears! LoL!
Mar 5, 1:58 PM
• !Report Abuse
Add a reply...

140 characters

PJP PowerShares Dynamic Pharmaceuticals Portfolio ETF

PJP

PowerShares Dynamic Pharmaceuticals Portfolio ETF